jueves, 14 de enero de 2021

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative - The Lancet Gastroenterology & Hepatology

From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative - The Lancet Gastroenterology & Hepatology
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)